Abstract
To evaluate the efficacy, bleeding profile and user satisfaction associated with the 13.5 mg total content levonorgestrel intrauterine contraceptive system (LNG-IUS13.5mg; Skyla in the US, Jaydess elsewhere) in postmenarcheal adolescents, and to evaluate the placement of LNG-IUS13.5mg in this group. Safety (primary outcome) data are presented in another abstract.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have